InfoCons Consumer Protection informs you – Remsima – Package Leaflet

Active substance	Infliximab
ATC code	L04AB02
EU authorisation number	EU/1/13/853
Marketing Authorisation Holder	Celltrion Healthcare Hungary Kft.
Therapeutic indication	Rheumatoid arthritis Remsima, in combination with methotrexate, is indicated for the reduction of signs and symptoms as well as the improvement in physical function in: • adult patients with active disease when the response to disease modifying antirheumatic drugs (DMARDs), including…
Last Commission decision	2025-11-17

Before anything else

Read all of this leaflet carefully before you start using this medicine because it contains important information for you.

• Keep this leaflet. You may need to read it again.
• Your doctor will also give you a patient reminder card, which contains important safety information you need to be aware of before and during your treatment with Remsima.
• When starting a new card, keep this card as a reference for 4 months after your last dose of Remsima.
• If you have any further questions, ask your doctor, pharmacist or nurse.
• This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours.
• If you get any side effects , talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. See section 4.

ℹ️ 1. What Remsima is and what it is used for

Remsima contains the active substance infliximab. Infliximab is a monoclonal antibody – a type of protein that attaches to a specific target in the body called TNF (tumour necrosis factor) alpha .

Remsima belongs to a group of medicines called ‘TNF blockers’. It is used in adults for the following inflammatory disease s:

• Rheumatoid arthritis
• Psoriatic arthritis
• Ankylosing spondylitis (Bechterew’s disease)
• Psoriasis
• Crohn’s disease
• Ulcerative colitis.

Remsima works by selectively attaching to TNF alpha and blocking its action. TNF alpha is involved in inflammatory processes of the body so blocking it can reduce the inflammation in your body.

Rheumatoid arthritis Rheumatoid arthritis is an inflammatory disease of the joints . If you have active rheumatoid arthritis you will first be given other medicines. If these medicines do not work well enough, you will be given Remsima which you will take with another medicine called methotrexate to:

• reduce the signs and symptoms of your disease,
• slow down the damage in your joints,
• improve your physical function.

Psoriatic arthritis Psoriatic arthritis is an inflammatory disease of the joints, usually accompanied by psoriasis. If you have active psoriatic arthritis you will first be given other medicines. If these medicines do not work well enough, you will be given Remsima to:

• reduce the signs and symptoms of your disease,
• slow down the damage in your joints,
• improve your physical function.

Ankylosing spondylitis (Bechterew’s disease) Ankylosing spondylitis is an inflammatory disease of the spine. If you have ankylosing spondylitis you will first be given other medicines. If these medicines do not work well enough, you will be given Remsima to:

• reduce the signs and symptoms of your disease,
• improve your physical function.

Psoriasis Psoriasis is an inflammatory disease of the skin. If you have moderate to severe plaque psoriasis, you will first be given other medicines or treatments, such as phototherapy. If these medicines or treatments do not work well enough, you will be given Rems ima to reduce the signs and symptoms of your disease.

Ulcerative colitis Ulcerative colitis is an inflammatory disease of the bowel. If you have ulcerative colitis you will first be given other medicines. If these medicines do not work well enough, you will be given Remsima to treat your disease.

Crohn’s disease Crohn’s disease is an inflammatory disease of the bowel. If you have Crohn’s disease you will first be given other medicines. If these medicines do not work well enough, you will be given Remsima to:

• treat active Crohn’s disease,
• reduce the number of abnormal openings (fistulae) between your bowel and your skin that have not been controlled by other medicines or surgery.

⚠️ 2. What you need to know before you use Remsima

You must not use Remsima if

• you are allergic to infliximab or any of the other ingredients of this medicine (listed in section 6),
• you are allergic to proteins that come from mice,
• you have tuberculosis (TB) or another serious infection such as pneumonia or sepsis (serious bacterial infection of the blood),
• you have heart failure that is moderate or severe.

Do not use Remsima if any of the above applies to you. If you are not sure, talk to your doctor before you are given Remsima .

Warnings and precautions

Talk to your doctor before or during treatment with Remsima if you have:

Had treatment with any medicine containing infliximab before

• Tell your doctor if you have had treatment with medicines containing infliximab in the past and are now starting Remsima treatment again.
• If you have had a break in your treatment with infliximab of more than 16 weeks, there is a higher risk for allergic reactions when you start the treatment again.

Local injection site reactions

• Some patients receiving infliximab via injection under the skin have experienced local injection site reactions. Signs of a local injection site reaction can include redness, pain, itching, swelling, hardness, bruising, bleeding, cold sensation, tingling sensation, irritation, rash, ulcer, hives, blisters and scab on the skin of the injection site .
• Most of these reactions are mild to moderate and mostly resolve on their own within a day.

Infections

• Tell your doctor before you are given Remsima if you have an infection even if it is a very minor one.
• Tell your doctor before you are given Remsima if you have ever lived in or travelled to an area where infections called histoplasmosis, coccidioidomycosis, or blastomycosis are common.

These infections are caused by specific types of fungi that can affect the lungs or other parts of your body.

• You may get infections more easily when you are being treated with Remsima. If you are 65 years of age or older, you have a greater risk.
• These infections may be serious and include tuberculosis, infections caused by viruses, fungi, bacteria or other organisms in the environment and sepsis that may be life -threatening.

Tell your doctor straight away if you get signs of infection during treatment with Remsima. Signs include fever, cough, flu -like signs, feeling unwell, red or hot skin, wounds or dental problems. Your doctor may recommend temporarily stopping Remsima.

Tuberculosis (TB)

• It is very important that you tell your doctor if you have ever had TB or if you have been in close contact with someone who has had or has TB.
• Your doctor will test you to see if you have TB. Cases of TB have been reported in patients treated with infliximab , even in patients who have already been treated with medicines for TB.

Your doctor will record these tests on your patient reminder card.

• If your doctor feels that you are at risk for TB, you may be treated with medicines for TB before you are given Remsima.

Tell your doctor straight away if you get signs of TB during treatment with Remsima. Signs include persistent cough, weight loss, feeling tired, fever, night sweats.

Hepatitis B virus

• Tell your doctor before you are using Remsima if you are a carrier of hepatitis B or have ever had it.
• Tell your doctor if you think you might be at risk of contracting hepatitis B.
• Your doctor should test you for hepatitis B virus.
• Treatment with TNF blockers such as Remsima may result in reactivation of hepatitis B virus in patients who carry this virus, which can be life -threatening in some cases.
• If you experience reactivation of hepatitis B, your doctor may need to stop your treatment and may give you medicines such as effective antiviral therapy with supportive treatment.

Heart problems

• Tell your doctor if you have any heart problems, such as mild heart failure.
• Your doctor will want to closely monitor your heart.

Tell your doctor straight away if you get new or worsening signs of heart failure during treatment with Remsima. Signs include shortness of breath or swelling of your feet.

Cancer and lymphoma

• Tell your doctor before you are given Remsima if you have or have ever had lymphoma (a type of blood cancer) or any other cancer.
• Patients with severe rheumatoid arthritis, who have had the disease for a long time, may be at higher risk of developing lymphoma.
• Patients taking Remsima may have an increased risk of developing lymphoma or another cancer.
• Some patients who have received TNF -blockers, including infliximab have developed a rare type of cancer called hepatosplenic T -cell lymphoma. Of these patients, most were teenage boys or young men and most had either Crohn’s disease or ulcerative colitis. This type of cancer has usually resulted in death. Almost all patients had also received medicines containing azathioprine or mercaptopurine in addition to TNF -blockers.
• Some patients treated with infliximab have developed certain kinds of skin cancer. If there are any changes in your skin or growths on the skin during or after therapy, tell your doctor.
• Some women being treated for rheumatoid arthritis with infliximab have developed cervical cancer. For women taking Remsima including those over 60 years of age, your doctor may recommend regular screening for cervical cancer.

Lung disease or heavy smoking

• Tell your doctor before you are given Remsima if you have a lung disease called chronic obstructive pulmonary disease (COPD) or if you are a heavy smoker.
• Patients with COPD and patients who are heavy smokers may have a higher risk of developing cancer with Remsima treatment.

Nervous system disease

• Tell your doctor before you are given Remsima if you have or have ever had a problem that affects your nervous system. This includes multiple sclerosis, Guillain -Barré syndrome, if you have fits or have been diagnosed with ‘optic neuritis’.

Tell your doctor straight away if you get symptoms of a nerve disease during treatment with Remsima.

Signs include changes in your vision, weakness in your arms or legs, numbness or tingling in any part of your body.

Abnormal skin openings

• Tell your doctor if you have any abnormal skin openings (fistulae) before you are given Remsima.

Vaccinations

• Talk to your doctor if you recently have had or are due to have a vaccine.
• You should receive recommended vaccinations before starting Remsima treatment. You may receive some vaccines during treatment with Remsima but you should not receive live vaccines (vaccines that contain a living but weakened infectious agent) while using R emsima because they may cause infections.
• If you received Remsima while you were pregnant, your baby may also be at higher risk for getting an infection as a result of receiving a live vaccine during the first year of life . It is important that you tell your baby’s doctors and other health care professionals about your Remsima use so they can decide when your baby should receive any vaccine, including live vaccines such as the BCG vaccine (used to prevent tuberculosis).
• If you are breast -feeding, it is important that you tell your baby’s doctors and other healthcare professionals about your Remsima use before your baby is given any vaccine. For more information see section on Pregnancy , breast -feeding and fertility .

Therapeutic infectious agents

• Talk to your doctor if you have recently received or are scheduled to receive treatment with a therapeutic infectious agent (such as BCG instillation used for the treatment of cancer).

Operations or dental procedures

• Tell your doctor if you are going to have any operations or dental procedures.
• Tell your surgeon or dentist that you are having treatment with Remsima by showing them your patient reminder card.

Liver problems

• Some patients receiving infliximab have developed serious liver problems.
• Tell your doctor straight away if you get symptoms of liver problems during treatment with Remsima. Signs include yello wing of the skin and eyes, dark -brown coloured urine, pain or swelling in the upper right side of the stomach area, joint pain, skin rashes, or fever.

Low b lood counts

• In some patients receiving infliximab, the body may not make enough of the blood cells that help fight infections or help stop bleeding.
• Tell your doctor straight away if you get symptoms of low blood counts during treatment with Remsima. Signs include persistent fever, bleed ing or bruising more easily , small red or purple spots caused by bleeding under the skin, or looking pale.

Immune system disorder

• Some patients receiving infliximab have dev eloped symptoms of an immu ne system disorder called lupus.
• Tell your doctor straight away if you develop symptoms of lupus during treatment with Remsima. Signs include joint pain or a rash on cheeks or arms that is sensitive to the sun .

Children and adolescents

Do not give this medicine to children and adolescents under 18 years of age because there are no data that show that this medicine is safe and works in this age group.

Other medicines and Remsima

Patients who have inflammatory diseases already take medicines to treat their problem. These medicines may cause side effects. Your doctor will advise you what other medicines you must keep using while you are having Remsima.

Tell your doctor if you are using, have recently used or might use any other medicines , including any other medicines to treat Crohn’s disease, ulcerative colitis, rheumatoid arthritis , ankylosing spondylitis, psoriatic arthritis or psoriasis or medicines obtained without a prescription, such as vitamins and herbal medicines.

In particular, tell your doctor if you are using any of the following medicines:

• Medicines that affect your immune system.
• Kineret (which contains anakinra). Remsima and Kineret should not be used together.
• Orencia (which contains abatacept). Remsima and Orencia should not be used together.

While using Remsima you should not receive live vaccines. If you were using Remsima during pregnancy or if you are receiving Remsima while breast -feeding , tell your baby’s doctor and other health care professionals caring for your baby about your Remsima use before the baby receives any vaccines.

If you are not sure if any of the above applies to you, talk to your doctor, pharmacist or nurse before using Remsima .

Pregnancy, breast -feeding and fertility

• If you are pregnant or breast -feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking this medicine. Remsima should only be used during pregnancy or while breast -feeding if your doctor feels it is necessary for you.
• You should avoid getting pregnant when you are being treated with Remsima and for 6 months after you stop being treated with it. Discuss the use of contraception during this time with your doctor.
• If you received Remsima during your pregnancy, your baby may have a higher risk for getting an infection.
• It is important that you tell your baby’s doctors and other healthcare professionals about your Remsima use before your baby is given any vaccine. If you received Remsima while pregnant, giving BCG vaccine (used to prevent tuberculosis) to your baby within 12 months after birth may result in infection with serious complications, including death. Live vaccines such as the BCG vaccine should not be given to your baby within 12 months after birth , unless your baby’s doctor recommends otherwise. For more inform ation see section on vaccination.
• If you are breast -feeding, it is important that you tell your baby’s doctors and other healthcare professionals about your Remsima use before your baby is given any vaccine. Live vaccines should not be given to your baby while you are breast -feeding unless your baby’s doctor recommends otherwise.
• Severely decreased numbers of white blood cells have been reported in infants born to women treated with infliximab during pregnancy. If your baby has continual fevers or infections, contact your baby’s doctor immediately.

Driving and using machines

Remsima is not likely to affect your ability to drive or use tools or machines. If you feel tired, dizzy, or unwell after having Remsima , do not drive or use any tools or machines.

Remsima contains sodium and sorbitol

This medicine contains less than 1 mmol sodium (23 mg) per dose, that is to say essentially ‘sodium – free’ and 45 mg sorbitol in each 120 mg dose.

Remsima contains polysorbate 80

This medicine contains 0. 5 mg of polysorbate 80 in each pre-filled pen which is equivalent to 0.5 mg/mL. Polysorbates may cause allergic reactions. Tell your doctor if you have any known allergies.

💊 3. How to use Remsima

Always use this medicine exactly as your doctor has told you. Check with your doctor if you are not sure.

Rheumatoid arthritis Your doctor will start your treatment with or without two infliximab intravenous infusion doses of 3 mg for every kg of body weight (given to you into a vein, usually in your arm, over a period of 2 hours). If infliximab intravenous infusion doses are given to start the treatment, they are administered 2 weeks apart via intravenous infusion. After 4 weeks from the last intravenous infusion, you will be given Remsima via injection under the skin (subcutaneous injection). If Remsima subcutaneous injection doses are given to start the treatment, Remsima 120 mg should be given as a subcutaneous injection followed by additional subcutaneous injections at 1, 2, 3 and 4 weeks after the first injection, then every 2 weeks thereafter.

The usual recommended dose of Remsima subcutaneous injection is 120 mg once every 2 weeks regardless of weight.

Psoriatic arthritis, ankylosing spondylitis (Bechterew’s disease) and psoriasis Your doctor will start your treatment with two infliximab intravenous infusion doses of 5 mg for every kg of body weight (given to you into a vein, usually in your arm, over a period of 2 hours). They are administered 2 weeks apart via intravenous infusion . After 4 weeks from the last intravenous infusion, you will be given Remsima via injection under the skin (subcutaneous injection).

The usual recommended dose of Remsima subcutaneous injection is 120 mg once every 2 weeks regardless of weight.

Crohn’s disease and ulcerative colitis Your doctor will start your treatment with two or three infliximab intravenous infusion doses of 5 mg for every kg of body weight (given to you into a vein, usually in your arm, over a period of 2 hours).

They are administered 2 weeks apart via intravenous infusion and additional intravenous infusion may be given 4 weeks after the second infusion . After 4 weeks from the last intravenous infusion, you will be given Remsima via injection under the skin (subcutaneous injection).

The usual recommended dose of Remsima subcutaneous injection is 120 mg once every 2 weeks regardless of weight.

How Remsima is given

• Remsima 120 mg solution for injection is administered by injection under the skin (subcutaneous use) only. It is important to check the product labels to ensure that the correct formulation is being given as prescribed.
• For patients with rheumatoid arthritis, y our doctor may start your Remsima treatment with or without infliximab intravenous infusion doses. For patients with ankylosing spondylitis, psoriatic arthritis or psoriasis, two infliximab intravenous infusion doses will be given to start your Remsima treatment. For patients with Crohn’s disease or ulcerative colitis , two or three infliximab intravenous infusion doses will be given to start your Remsima treatment.
• For rheumatoid arthritis patients, if Remsima treatment is initiated without two infliximab intravenous infusion doses, the table below shows how often you will usually have Remsima 120 mg subcutaneous after your first dose.

2nd dose 1 week after your 1st dose 3rd dose 2 weeks after your 1st dose 4th dose 3 weeks after your 1st dose 5th dose 4 weeks after your 1st dose Further doses 6 weeks after your 1st dose and e very 2 weeks thereafter

• Infliximab intravenous infusion doses will be given 2 weeks apart by your doctor or nurse and additional intravenous infusion may be given 4 weeks after the second infusion for Crohn’s disease and ulcerative colitis patients under your doctor’s discretion to start your Remsima treatment. The first Remsima subcutaneous injection will be given 4 weeks after the last intravenous infusion followed by Remsima subcutaneous injections given every 2 weeks.
• The first subcutaneous injection of Remsima will be administered under the supervision of your doctor .
• After p roper training , if you feel you are well -trained and confident to inject Remsima yourself, your doctor may allow you to inject subsequent doses of Remsima yourself at home .
• Talk to your doctor if you have any questions about giving yourself an injection. You will find detailed “Instructions for Use” at the end of this leaflet.

If you use more Remsima than you should

If you have used more Remsima than you should (either by injecting too much on a single occasion or by using it too frequently), talk to a doctor, pharmacist or nurse immediately. Always have the outer carton of the medicine with you, even if it is empty .

If you forget to use Remsima

Missed dose for up to 7 days If you miss a dose of Remsima for up to 7 days, after the original scheduled dose, you should take the missed dose immediately. Take your next dose on the next originally planned date and then follow the original dosing schedule.

Missed dose for 8 days or more If you miss a dose of Remsima for 8 days or more, after the original scheduled dose, you should not take the missed dose. Take your next dose on the next originally planned date and then follow the original dosing schedule.

If you are not sure when to inject Remsima, call your doctor.

If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse .

❗ 4. Possible side effects

Like all medicines, this medicine can cause side effects, although not everybody gets them. Most side effects are mild to moderate. However some patients may experience serious side effects and may require treatment. Side effects may also occur after your treatment with Remsima has stopped.

Tell your doctor straight away if you notice any of the following:

• Signs of an allergic reaction such as swelling of your face, lips, mouth or throat which may cause difficulty in swallowing or breathing, skin rash, hives, swelling of the hands, feet or ankles. Some of these reactions may be serious or life -threatening. An allergic reaction could happen within 2 hours of your injection or later. More signs of allergic side effects that may happen up to 12 days after your injection include pain in the muscles, fever, joint or jaw pain, sore throat or headache .
• Signs of a local injection site reaction such as redness, pain, itching, swelling, hardness, bruising, bleeding, cold sensation, tingling sensation, irritation, rash, ulcer, hives, blisters and scab.
• Signs of a heart problem such as chest discomfort or pain, arm pain, stomach pain, shortness of breath, anxiety, lightheadedness, dizziness, fainting, sweating, nausea (feeling sick), vomiting, fluttering or pounding in your chest, a fast or a slow heartbeat, and swelling of your feet.
• Signs of infection (including TB) such as fever, feeling tired, cough which may be persistent , shortness of breath, flu -like symptoms, weight loss, night sweats, diarrhoea, wounds, collection of pus in the gut or around the anus (abscess), dental problems or burning sensation when urinating .
• Possible signs of cancer including but not limited to swelling of lymph nodes, weight loss, fever, unusual skin nodules, changes in moles or skin colouring, or unusual vaginal bleeding.
• Signs of a lung problem such as coughing, breathing difficulties or tightness in the chest .
• Signs of a nervous system problem (including eye problems) such as signs of a stroke (sudden numbness or weakness of your face, arm or leg, especially on one side of your body; sudden confusion, trouble speaking or understanding; trouble seeing in one or both eyes, trouble walking, dizziness, loss of balance or coordinati on or a severe headache), fits, tingling /numbness in any part of your body, or weakness in arms or legs, changes in eyesight such as double vision or other eye problems .
• Signs of a liver problem (including hepatitis B infection when you have had hepatitis B in the past) such as yellowing of the skin or eyes, dark -brown coloured urine , pain or swelling in the upper right side of the stomach area, joint pain, skin rashes, or fever .
• Signs of an immune system disorder called lupus such as joint pain or a rash on cheeks or arms that is sensitive to the sun (lupus) or cough, shortness of breath, fever or skin rash (sarcoidosis).
• Signs of low blood count s such as persistent fever, bleeding or bruising more easily , small red or purple spots caused by bleeding under the skin, or looking pale.
• Signs of serious skin problems such as reddish -target -like spots or circular patches often with central blisters on the trunk, large areas of peeling and shedding (exfoliating) skin, ulcers of mouth, throat, nose, genitals and eyes or small pus -filled bumps that can spread over the bod y.

These skin reactions can be accompanied by fever.

Tell your doctor straight away if you notice any of the above.

The following side effects have been observed with Remsima:

Very common : may affect more than 1 in 10 people

• Stomach pain, feeling sick
• Viral infections such as herpes or flu
• Upper respiratory infections such as sinusitis
• Headache
• Side effect due to an injection
• Pain.

Common : may affect up to 1 in 10 people

• Changes in how your liver works, increase in liver enzymes (shown in blood tests)
• Lung or chest infections such as bronchitis or pneumonia
• Difficult or painful breathing, chest pain
• Bleeding in the stomach or intestines, diarrhoea, indigestion, heartburn, constipation
• Nettle -type rash (hives), itchy rash or dry skin
• Balance problems or feeling dizzy
• Fever, increased sweating
• Circulation problems such as low or high blood pressure
• Bruising, hot flush or nosebleed, warm, red skin (flushing)
• Feeling tired or weak
• Bacterial infections such as blood poisoning, abscess or infection of the skin (cellulitis)
• Infection of the skin due to a fungus
• Blood problems such as anaemia or low white blood cell count
• Swollen lymph nodes
• Depression, problems sleeping
• Eye problems, including red eyes and infections
• Fast heart beat (tachycardia) or palpitations
• Pain in the joints, muscles or back
• Urinary tract infection
• Psoriasis, skin problems such as eczema and hair loss
• Reactions at the injection site such as pain, swelling, redness or itching
• Chills, a build -up of fluid under the skin causing swelling
• Feeling numb or having a tingling feeling.

Uncommon : may affect up to 1 in 100 people

• Shortage of blood supply, swelling of a vein
• Collection of blood outside the blood vessels (haematoma) or bruising
• Skin problems such as blistering, warts, abnormal skin colouration or pigmentation, or swollen lips, or thickening of the skin, or red, scaly, and flaky skin
• Severe allergic reactions (e.g. anaphylaxis), an immune system disorder called lupus, allergic reactions to foreign proteins
• Wounds taking longer to heal
• Swelling of the liver (hepatitis) or gall bladder, liver damage
• Feeling forgetful, irritable, confused, nervous
• Eye problems including blurred or reduced vision, puffy eyes or sties
• New or worsening heart failure, slow heart rate
• Fainting
• Convulsions, nerve problems
• A hole in the bowel or blockage of the intestine, stomach pain or cramps
• Swelling of your pancreas (pancreatitis)
• Fungal infections such as yeast infection , or fungal infection of the nails
• Lung problems (such as oedema)
• Fluid around the lungs (pleural effusion)
• Narrowed airway in the lungs, causing difficulty breathing
• Inflamed lining of the lung, causing sharp chest pains that feel worse with breathing (pleurisy)
• Tuberculosis
• Kidney infections
• Low platelet count, too many white blood cells
• Infections of the vagina
• Blood test result showing ‘ antibod ies’ against your own body
• Changes in cholesterol and fat levels in the blood .
• Weight gain (for most patients, the weight gain was small) .

Rare : may affect up to 1 in 1,000 people

• A type of blood cancer (lymphoma)
• Your blood not supplying enough oxygen to your body, circulation problems such as narrowing of a blood vessel
• Inflammation of the lining of the brain (meningitis)
• Infections due to a weakened immune system
• Hepatitis B infection when you have had hepatitis B in the past
• Inflamed liver caused by a problem with the immune system (autoimmune hepatitis)
• Liver problem that causes yellowing of the skin or eyes (jaundice)
• Abnormal tissue swelling or growth
• Severe allergic reaction that may cause loss of consciousness and could be life -threatening (anaphylactic shock)
• Swelling of small blood vessels (vasculitis)
• Immune disorders that could affect the lungs, skin and lymph nodes (such as sarcoidosis)
• Collections of immune cells resulting from an inflammatory response (granulomatous lesions)
• Lack of interest or emotion
• Serious skin problems such as toxic epidermal necrolysis, Stevens -Johnson syndrome and acute generalised exanthematous pustulosis
• Other skin problems such as erythema multiforme, blisters and peeling skin, or boils (furunculosis)
• Serious nervous system disorders such as transverse myelitis, multiple sclerosis -like disease, optic neuritis and Guillain -Barré syndrome
• Inflammation in the eye that may cause changes in the vision, including blindness
• Fluid in the lining of the heart (pericardial effusion)
• Serious lung problems (such as interstitial lung disease)
• Melanoma (a type of skin cancer )
• Cervical cancer
• Low blood counts, including a severely decreased number of white blood cells
• Small red or purple spots caused by bleeding under the skin
• Abnormal values of a blood protein called ‘complement factor’ which is part of the immune system
• Lichenoid reactions (itchy reddish -purple skin rash and/or threadlike white -grey lines on mucous membranes).

Not known : frequency cannot be estimated from the available data

• Cancer
• A rare blood cancer affecting mostly young men (hepatosplenic T -cell lymphoma)
• Liver failure
• Merkel cell carcinoma (a type of skin cancer )
• Kaposi’s sarcoma, a rare cancer related to infection with human herpes virus 8. Kaposi’s sarcoma most commonly appears as purple lesions on the skin.
• Worsening of a condition called dermatomyositis (seen as a skin rash accompanying muscle weakness)
• Heart attack
• Stroke
• Temporary loss of sight during or within 2 hours of infusion
• Infection due to a live vaccine because of a weakened immune system .

Reporting of side effects

If you get any side effects, talk to your doctor, pharmacist, or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V . By reporting side effects you can help provide more information on the safety of this medicine.

🌡️ 5. How to store Remsima

• Keep this medicine out of the sight and reach of children.
• Do not use this medicine after the expiry date which is stated on the label and the carton after “EXP”. The expiry date refers to the last day of that month.
• Store in a refrigerator (2°C – 8°C). Do not freeze. Keep the pre-filled pen in the outer carton in order to protect from light.
• This medicine can also be stored in the original carton outside of refrigerated storage up to a maximum of 25°C for a single period of up to 28 days, but not beyond the original expiry date.

In this situation, do not return to refrigerated storage again. Write the new expiry date on the carton including day/month/year. Discard this medicine if not used by the new expiry date or the expiry date pr inted on the carton, whichever is earlier.

• Do not throw away any medicines via w astewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.

📦 6. Contents of the pack and other information

What Remsima contains

• The active substance is infliximab. Each 1 ml single dose pre-filled pen contains 120 mg of infliximab.
• The other ingredients are acetic acid, sodium acetate trihydrate, sorbitol (E420) , polysorbate 80 (E433) and water for injection s.

What Remsima looks like and contents of the pack

Remsima is a clear to opalescent, colourless to pale brown solution which is supplied as a single use pre-filled pen.

Each pack contains 1 pre -filled pen with 2 alcohol pads, 2 pre -filled pens with 2 alcohol pads, 4 pre-filled pens with 4 alcohol pads or 6 pre -filled pens with 6 alcohol pads.

Not all pack sizes may be marketed.

Marketing Authorisation Holder

Celltrion Healthcare Hungary Kft.

1062 Budapest Váci út 1 -3. WestEnd Office Building B torony Hungary

Manufacturer

Millmount Healthcare Ltd.

Block 7 City North Business Campus Stamullen, Co. Meath K32 YD60 Ireland Nuvisan GmbH Wegenerstraße 13, 89231 Neu -Ulm, Germany Nuvisan France SARL 2400, Route des Colles, 06410, Biot, France Kymos, SL Ronda De Can Fatjó 7B, Parc Tecnològic del Vallès , Cerdanyola del Vallès, Barcelona, 08290, Spain Midas Pharma GmbH Rheinstraße 49 55218 Ingelheim am Rhein Germany For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder:

België/Belgique/Belgien Celltrion Healthcare Belgium BVBA Tél/Tel: + 32 1528 7418 [email protected] Lietuva Celltrion Healthcare Hungary Kft.

1062 Budapest Váci út 1 -3. WestEnd Office Building B torony Vengrija България Celltrion Healthcare Hungary Kft.

1062 Budapest Váci út 1 -3. WestEnd Office Building B torony Унгария Luxembourg/Luxemburg Celltrion Healthcare Belgium BVBA Tél/Tel: + 32 1528 7418 [email protected] Česká republika Celltrion Healthcare Hungary Kft.

1062 Budapest Váci út 1 -3. WestEnd Office Building B torony Maďarsko Magyarország Celltrion Healthcare Hungary Kft.

1062 Budapest Váci út 1 -3. WestEnd Office Building B torony Magyarország Danmark Celltrion Healthcare Denmark ApS Tlf: +45 3535 2989 Malta Mint Health Ltd .

Tel: +356 2093 9800 [email protected] info@ mint.com.mt Deutschland Celltrion Healthcare Deutschland GmbH Tel: + 49 30346494150 [email protected] Nederland Celltr ion Healthcare Netherlands B.V.

Tel: + 31 20 888 7300 [email protected] Eesti Celltrion Healthcare Hungary Kft.

1062 Budapest Váci út 1 -3. WestEnd Office Building B torony Ungari Norge Celltrion Healthcare Norway AS [email protected] Ελλάδα ΒΙΑΝΕΞ Α.Ε.

Τηλ: +30 210 8009111 – 120 Ö sterreich Astro -Pharma GmbH Tel: +43 1 97 99 860 [email protected] España Kern Pharma, S.L.

Tel: +34 93 700 25 25 Polska Celltrion Healthcare Hungary Kft.

1062 Budapest Váci út 1 -3. WestEnd Office Building B torony Węgry France Celltrion Healthcare France SAS Tél: + 33 (0)1 71 25 27 00 Portugal PharmaKERN Portugal – Produtos Farmacêuticos, Sociedade Unipessoal, Lda.

Tel: +351 214 200 290 Hrvatska OKTAL PHARMA d.o.o.

Tel: +385 1 6595 777 oktal -pharma@oktal -pharma.hr România Celltrion Healthcare Hungary Kft.

1062 Budapest Váci út 1 -3. WestEnd Office Building B torony Ungaria Ireland Celltrion Healthcare Ireland Limited Tel: +353 1 223 4026 Slovenija OKTAL PHARMA d.o.o.

Tel: +386 1 519 29 22 info@oktal -pharma.si Ísland Vistor hf.

Sí mi: +354 535 7000 Slovenská republika Celltrion Healthcare Hungary Kft.

1062 Budapest Váci út 1 -3. WestEnd Office Building B torony Maďarsko Italia Celltrion Healthcare Italy S.r.l.

Via Luigi Galvani, 24 – 20124 Milano (MI) Tel: + 39 0247 927040 Suomi/Finland Celltrion Healthcare Finland Oy.

Puh/Tel: +358 29 170 7755 [email protected] Κύπρος C.A. Papaellinas Ltd Τηλ: + 3 57 22741741 Sverige Celltrion Healthcare Hungary Kft.

1062 Budapest Váci út 1 -3. WestEnd Office Building B torony Ungern Latvija Celltrion Healthcare Hungary Kft.

1062 Budapest Váci út 1 -3. WestEnd Office Building B torony Ungārija United Kingdom (Northern Ireland ) Celltrion Healthcare Ireland Limited Tel: + 353 1 223 4026 This leaflet was last revised in {MM/YYYY}.

Other sources of information Detailed information on this medicine is available on the European Medicines Agency web site: https://www.ema.europa.eu .

This leaflet is available in all EU/EEA languages on the European Medicines Agency website.

7. Instructions for use Read carefully these instructions before using the Remsima pen. Consult your healthcare provider if you have questions about using the Remsima pen.

Important information

• Use the pen ONLY if your healthcare provider has trained you on the right way to prepare for and to give an injection.
• Ask your healthcare provider how often you will need to give an injection.
• Rotate the injection site each time you give an injection. Each new injection site should be at least 3 cm away from the previous injection site.
• Do not use the pen if it has been dropped or is visibly damaged. A damaged pen may not function properly.
• Do not reuse the pen.
• Do not shake the pen at any time.

About the Remsima pen Parts of the pen (see Figure A ):

Figure A

• Do not remove the cap until you are ready to inject. Once you remove the cap, do not recap the pen.

Prepare for the injection 1. Gather the supplies for the injection. a. Prepare a clean, flat surface, such as a table or countertop, in a well -lit area. b. Remove the pen from the carton stored in your refrigerator. c. Ensure you have the following supplies:

• Pen
• Alcohol swab
• Cotton ball or gauze*
• Adhesive bandage*
• Sharps disposal container* *Items not included in the carton.

2. Inspect the pen.

Do not use the pen if

• It is cracked or damaged.
• The expiration date has passed.

3. Inspect the medicine (see Figure B ).

The liquid should be clear and colourless to pale brown.

Do not use the pen if the liquid is cloudy, discoloured or

contains particles in it.

Note: You may see air bubbles in the liquid. This is normal.

Figure B 4. Wait 30 minutes. a. Leave the pen at room temperature for 30 minutes to allow it to naturally warm up.

Do not warm the pen using heat sources such as hot water or a microwave.

5. Choose an injection site (see Figure C). a. Select an injection site. You may inject into:

• The front of the thighs.
• The abdomen except for the 5 cm around the belly button (navel).
• The outer area of the upper arms (caregiver ONLY).

Do not inject into skin that is within 5 cm of your belly button (navel), or is tender, damaged, bruised, or scarred.

Note: Rotate the injection site each time you give an injection. Each new injection site should be at least 3 cm away from the previous injection site.

Figure C 6. Wash your hands. a. Wash your hands with soap and water and dry them thoroughly.

7. Clean the injection site. a. Clean the injection site with an alcohol swab. b. Let the skin dry before injecting.

Do not blow on or touch the injection site again before giving the injection.

Give the injection 8. Remove the cap (see Figure D ). a. Pull the olive green cap straight off and set it aside.

Do not touch the needle cover. Doing so may result in a needle stick injury.

Note: It is normal to see a few drops of liquid come out of the needle upon the cap removal.

Figure D 9. Place the pen on the injection site (see Figure E ). a. Hold the pen so that you can see the w indow. b. Without pinching or stretching the skin, place the pen over the injection site at a 90 -degree angle.

Figure E 10. Start the injection (see Figure F ). a. Press the pen firmly against the skin .

Note: When the injection starts you will hear the 1st loud “click” and the olive green p lunger rod will begin to fill the w indow. b. Keep holding the pen firmly against the skin and listen for the 2nd loud “click.” Figure F 11. Finish the injection (see Figure G ). a. After you hear the 2nd loud “click,” continue to hold the pen firmly against the skin and count slowly to at least five to ensure you inject the full dose.

Figure G 12. Remove the pen from the injection site. a. Look at the pen and confirm that the olive green plunger rod is filling the window completely. b. Lift the pen from the injection site (see Figure H). c. Gently press a cotton ball or gauze over the injection site and apply an adhesive bandage, if necessary.

Do not rub the injection site.

Note: After you remove the pen from the injection site, the needle will be automatically covered (see Figure I).

Note: If the olive green plunger rod does not fill the window completely, you did not receive your full dose.

Do not reuse the pen in this case. Call your healthcare provider immediately.

Figure H Figure I After the injection 13. Dispose of the pen (see Figure J ). a. Put the used pen in an approved sharps disposal container immediately after use . b. If you do not have an approved sharps disposal container, you may use a household container that is:

• made of a heavy -duty plastic;
• able to close with a tight -fitting, puncture -resistant lid, without sharps being able to come out;
• upright and stable during use;
• leak-resistant; and
• properly labelled to warn of hazardous waste inside the container. c. When your sharps disposal container is almost full, it should be disposed of in accordance with local requirements.

Do not recap the pen .

Note: Keep the pen and sharps disposal container out of the sight and reach of children .

Figure J Package leaflet: Information for the user Remsima 40 mg/mL concentrate for solution for infusion infliximab Read all of this leaflet carefully before you start using this medicine because it contains important information for you .

• Keep this leaflet. You may need to read it again.
• Your doctor will also give you a patient reminder card, which contains important safety information you need to be aware of before and during your treatment with Remsima.
• When starting a new card, keep this card as a reference for 4 months after your last dose of Remsim a.
• If you have any further questions, ask your doctor.
• This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours.
• If you get any side effects , talk to your doctor. This includes any possible side effects not listed in this leaflet. See section 4.

What is in this leaflet 1. What Remsima is and what it is used for 2. What you need to know before you use Remsima 3. How Remsima will be given 4. Possible side effects 5. How to store Remsima 6. Contents of the pack and other information 1. What Remsima is and what it is used for Remsima contains the active substance infliximab . Infliximab is a monoclonal antibody – a type of protein that attaches to a specific target in the body called TNF (tumour necrosis factor) alpha.

Remsima belongs to a group of medicines called ‘TNF blockers’. It is used in adults for the following inflammatory diseases:

• Rheumatoid arthritis
• Psoriatic arthritis
• Ankylosing spondylitis (Bechterew’s disease)
• Psoriasis.

Remsima is also used in adults and children 6 years of age or older for:

• Crohn’s disease
• Ulcerative colitis.

Remsima works by selectively attaching to TNF alpha and blocking its action. TNF alpha is involved in inflammatory processes of the body so blocking it can reduce the inflammation in your body.

Rheumatoid arthritis Rheumatoid arthritis is an inflammatory disease of the joints . If you have active rheumatoid arthritis you will first be given other medicines. If these medicines do not work well enough, you will be given Remsima which you will take with another medicine called methotrexate to:

• reduce the signs and symptoms of your disease,
• slow down the damage in your joints,
• improve your physical function.

Psoriatic arthritis Psoriatic arthritis is an inflammatory disease of the joints, usually accompanied by psoriasis. If you have active psoriatic arthritis you will first be given other medicines. If these medicines do not work well enough , you will be given Remsima to:

• reduce the signs and symptoms of your disease,
• slow down the damage in your joints,
• improve your physical function.

Ankylosing spondylitis (Bechterew’s disease) Ankylosing spondylitis is an inflammatory disease of the spine. If you have ankylosing spondylitis you will first be given other medicines. If these medicines do not work well enough , you will be given Remsima to:

• reduce the signs and symptoms of your disease,
• improve your physical function.

Psoriasis Psoriasis is an inflammatory disease of the skin. If you have moderate to severe plaque psoriasis, you will first be given other medicines or treatments, such as phototherapy. If these medicines or treatments do not work well enough , you will be given Remsima to reduce the signs and symptoms of your disease.

Ulcerative colitis Ulcerative colitis is an inflammatory disease of the bowel. If you have ulcerative colitis you will first be given other medicines. If these medicines do not work well enough , you will be given Remsima to treat your disease.

Crohn’s disease Crohn’s disease is an inflammatory disease of the bowel. If you have Crohn’s disease you will first be given other medicines. If these medicines do not work well enough , you will be given Remsima to:

• treat active Crohn’s disease,
• reduce the number of abnormal openings (fistulae) between your bowel and your skin that have not been controlled by other medicines or surgery.

2. What you need to know before you use Remsima You must not be given Remsima if

• you are allergic to infliximab or any of the other ingredients of this medicine (listed in section 6),
• you are allergic to proteins that come from mice,
• you have tuberculosis (TB) or another serious infection such as pneumonia or sepsis (serious bacterial infection of the blood),
• you have heart failure that is moderate or severe.
• you have hereditary fructose intolerance, a quite rare genetic condition where the enzyme for breaking down fructose is not produced.

Do not use Remsima if any of the above applies to you. If you are not sure, talk to your doctor before you are given Remsima.

Warnings and precautions

Talk to your doctor before or during treatment with Remsima if you have:

Had treatment with any medicine containing infliximab before

• Tell your doctor if you have had treatment with medicines containing infliximab in the past and are now starting Remsima treatment again.
• If you have had a break in your treatment with infliximab of more than 16 weeks, there is a higher risk for allergic reactions when you start the treatment again.

Infections

• Tell your doctor before you are given Remsima if you have an infection even if it is a very minor one.
• Tell your doctor before you are given Remsima if you have ever lived in or travelled to an area where infections called histoplasmosis, coccidioidomycosis, or blastomycosis are common.

These infections are caused by specific types of fungi that can affect the lungs or other parts of your body.

• You may get infections more easily when you are being treated with Remsima. If you are 65 years of age or older, you have a greater risk.
• These infections may be serious and include tuberculosis, infections caused by viruses, fungi , bacteria or other organisms in the environment and sepsis that may be life -threatening.

Tell your doctor straight away if you get signs of infection during treatment with Remsima. Signs include fever, cough, flu -like signs, feeling unwell, red or hot skin, wounds or dental problems. Your doctor may recommend temporar ily stopping Remsima.

Tuberculosis (TB)

• It is very important that you tell your doctor if you have ever had TB or if you have been in close contact with someone who has had or has TB.
• Your doctor will test you to see if you have TB. Cases of TB have been reported in patients treated with infliximab, even in patients who have already been treated with medicines for TB .

Your doctor will record these tests on your patient reminder card.

• If your doctor feels that you are at risk for TB, you may be treated with medicines for TB before you are given Remsima.

Tell your doctor straight away if you get signs of TB during treatment with Remsima. Signs include persistent cough, weight loss, feeling tired, fever, night sweats.

Hepatitis B virus

• Tell your doctor before you are given Remsima if you are a carrier of hepatitis B or have ever had it .
• Tell your doctor if you think you might be at risk of contracting hepatitis B .
• Your doctor should test you for hepatitis B virus .
• Treatment with TNF blockers such as Remsima may result in reactivation of hepatitis B virus in patients who carry this virus, which can be life -threatening in some cases.
• If you experience reactivation of hepatitis B, your doctor may need to stop your treatment and may give you medicines such as effective antiviral therapy with supportive treatment.

Heart problems

• Tell your doctor if you have any heart problems, such as mild heart failure.
• Your doctor will want to closely monitor your heart.

Tell your doctor straight away if you get new or worsening signs of heart failure during treatment with Remsima. Signs include shortness of breath or swelling of your feet.

Cancer and lymphoma

• Tell your doctor before you are given Remsima if you have or have ever had lymphoma (a type of blood cancer) or any other cancer.
• Patients with severe rheumatoid arthritis, who have had the disease for a long time, may be at higher risk of developing lymphoma.
• Children and adults taking Remsima may have an increased risk of developing lymphoma or another cancer.
• Some patients who have received TNF -blockers, including infliximab have developed a rare type of cancer called hepatosplenic T -cell lymphoma. Of these patients, most were teenage boys or young men and most had either Crohn’s disease or ulcerative colitis. This type of cancer has usually resulted in death. Almost all patients had also received medicines containing azathioprine or mercaptopurine in addition to TNF -blockers.
• Some patients treated with infliximab have developed certain kinds of skin cancer. If there are any changes in your skin or growths on the skin during or after therapy, tell your doctor.
• Some women being treated for rheumatoid arthritis with infliximab have developed cervical cancer. For women taking Remsima including those over 60 years of age, your doctor may recommend regular screen ing for cervical cancer.

Lung disease or heavy smoking

• Tell your doctor before you are given Remsima if you have a lung disease called chronic obstructive pulmonary disease (COPD) or if you are a heavy smoker.
• Patients with COPD and patients who are heavy smokers may have a higher risk of developing cancer with Remsima treatment.

Nervous system disease

• Tell your doctor before you are given Remsima if you have or have ever had a problem that affects your nervous system. This includes multiple sclerosis, Guillain -Barré syndrome, if you have fits or have been diagnosed with ‘optic neuritis’.

Tell your doctor straight away if you get symptoms of a nerve disease during treatment with Remsima.

Signs include changes in your vision, weakness in your arms or legs, numbness or tingling in any part of your body.

Abnormal skin openings

• Tell your doctor if you have any abnormal skin openings (fistulae) before you are given Remsima.

Vaccinations

• Talk to your doctor if you recently have had or are due to have a vaccine.
• You should receive recommended vaccinations before starting Rem sima treatment. You may receive some vac cines during treatment with Remsima but you should not receive live vaccines (vaccines that contain a living but weakened infectious agent) while using Remsima because they may cause infections.
• If you received Remsima while you were pregnant, your baby may also be at higher risk for getting an infection as a result of receiving a live vaccine during the first year of life . It is important that you tell your baby’s doctors and other health care professionals about your Remsima use so they can decide when your baby should receive any vaccine, including live vaccines such as the BCG vaccine (used to prevent tuberculosis).
• If you are breast -feeding, it is important that you tell your baby’s doctors and other healthcare professionals about your Remsima use before your baby is given any vaccine. For more information see section on Pregnancy , breast -feeding and fertility.

Therapeutic infectious agents

• Talk to your doctor if you have recently received or are scheduled to receive treatment with a therapeutic infectious agent (such as BCG instillation used for the treatment of cancer).

Operations or dental procedures

• Tell your doctor if you are going to have any operations or dental procedures.
• Tell your surgeon or dentist that you are having treatment with Remsima by showing them your patient reminder card.

Liver problems

• Some patients receiving infliximab have developed serious liver problems.
• Tell your doctor straight away if you get symptoms of liver problems during treatment with Remsima. Signs include yello wing of the skin and eyes, dark -brown coloured urine, pain or swelling in the upper right side of the stomach area, joint pain, skin rashes, or fever.

Low blood counts

• In some patients receiving infliximab, the body may not make enough of the blood cells that help fight infections or help stop bleeding.
• Tell your doctor straight away if you get symptoms of low blood counts during treatment with Remsima . Signs include persistent fever, bleeding or bruising more easily, small red or purple spots caused by bleeding under the skin, or looking pale .

Immune system disorder

• Some patients receiving infliximab have dev eloped symptoms of an immu ne system disorder called lupus.
• Tell your doctor straight away if you develop symptoms of lupus during treatment with Remsima. Signs include joint pain or a rash on cheeks or arms that is sensitive to the sun .

Children and adolescents

The information above also applies to children and adolescents. In addition:

• Some children and teenage patients who have received TNF -blockers such as infliximab have developed cancers, including unusual types, which sometimes resulted in death.
• More children taking infliximab developed infections as compared to adults.
• Children should receive recommended vaccinations before starting Remsima treatment.

Children may receive some vaccines during treatment with Remsima but should not receive live vaccines while using Remsima .

Remsima should only be used in children if they are being treated for Crohn’s disease or ulcerative colitis. These children must be 6 years of age or older.

If you are not sure if any of the above applies to you, talk to your doctor before you are given Remsima.

Other medicines and Remsima

Patients who have inflammatory diseases already take medicines to treat their problem. These medicines may cause side effects. Your doctor will advise you what other medicines you must keep using while you are having Remsima.

Tell your doctor if you are using, have recently used or might use any other medicines, including any other medicines to treat Crohn’s disease, ulcerative colitis, rheumatoid arthritis, ankylosing spondylitis, psoriati c arthriti s or psoriasi s or medicines obtained without a prescription, such as vitamins and herbal medicines.

In particular, tell your doctor if you are using any of the following medicines:

• Medicines that affect your immune system.
• Kineret (which contains anakinra). Remsima and Kineret should not be used together.
• Orencia (which contains abatacept). Remsima and Orencia should not be used together.

While using Remsima you should not receive live vaccines. If you were using Remsima during pregnancy or if you are receiving Remsima while breast -feeding , tell your baby’s doctor and other health care professionals caring for your baby about your Remsima use before the baby receives any vaccines.

If you are not sure if any of the above applies to you, talk to your doctor or pharmacist before using Remsima.

Pregnancy , breast -feeding and fertility

• If you are pregnant or breast -feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking this medicine. Remsima should only be used during pregnancy or while breast -feeding if your doctor feels it is necessary for you .
• You should avoid getting pregnant when you are being treated with Remsima and for 6 months after you stop being treated with it. Discuss the use of contraception during this time with your doctor .
• If you received Remsima during your pregnancy, your baby may have a higher risk for getting an infection.
• It is important that you tell your baby’s doctors and other healthcare professionals about your Remsima use before your baby is given any vaccine . If you received Remsima while pregnant, giving BCG vaccine (used to prevent tuberculosis) to your baby within 12 months after birth may result in infection with serious complications, including death. Live vaccines such as the the BCG vaccine should not be given to your baby within 12 months after birth , unless your baby’s doctor recommends otherwise . For more information see section on vaccination.
• If you are breast -feeding, it is important that you tell your baby’s doctors and other healthcare professionals about your Remsima use before your baby is given any vaccine. Live vaccines should not be given to your baby while you are breast -feeding unless your baby’s doctor recommends otherwise.
• Severely decreased numbers of white blood cells have been reported in infants born to women treated with infliximab during pregnancy. If your baby has continual fevers or infections, contact your baby’s doctor immediately.

Driving and using machines

Remsima is not likely to affect your ability to drive or use tools or machines. If you feel tired, dizzy , or unwell after having Remsima, do not drive or use any tools or machines.

Remsima contains sorbitol

Sorbitol is a source of fructose. If you have hereditary fructose intolerance (HFI), a rare genetic disorder, you must not receive this medicine. Patients with HFI cannot break down fructose, which may cause serious side effects.

You must tell your doctor before receiving this medicine if you (or your child) have HFI or if your child can no longer take sweet foods or drinks because they feel sick, vomit or get unpleasant effects such as bloating, stomach cramps or diarrhoea.

Remsima contains polysorbate 80

This medicine contains 1.3 mg of polysorbate 80 in each 100 mg vial which is equivalent to 0.5 mg/mL, and 4.4 mg of polysorbate 80 in each 350 mg vial which is equivalent to 0.5 mg/mL.

Polysorbates may cause allergic reactions. Tell your doctor if you have any known allergies.

Remsima contains sodium

This medicine contains less than 1 mmol sodium (23 mg) per dose, that is to say essentially ‘sodium – free’. However, before Remsima is given to you, it is mixed with a solution that contains sodium. Talk to your doctor if you are on a low salt diet.

3. How Remsima will be given Rheumatoid arthritis The usual dose is 3 mg for every kg of body weight.

Psoriatic arthritis, ankylosing spondylitis (Bechterew’s disease), psoriasis, ulcerative colitis and Crohn’s disease The usual dose is 5 mg for every kg of body weight.

How Remsima is given

• Remsima will be given to you by your doctor or nurse.
• Your doctor or nurse will prepare the medicine for infusion.
• The medicine will be given as an infusion (drip) (over 2 hours) into one of your veins , usually in your arm. After the third treatment, your doctor may decide to give you r dose of Remsima over 1 hour.
• You will be monitored while you are given Remsima and also for 1 to 2 hours after wards .

How much Rem sima is given

• The doctor will decide your dose and how often you will be given Remsima . This will depend on your disease, weight and how well you respond to Remsima .
• The table below shows how often you will usually have this medicine after your first dose .

2nd dose 2 weeks after your 1st dose 3rd dose 6 weeks after your 1st dose Further doses Every 6 to 8 weeks depending on your disease Use in children and adolescents In children (6 years of age or older) treated for Crohn’s disease or ulcerative colitis, the recommended dose is the same as for adults.

If you are given too much Remsima As this medicine is being given by your doctor or nurse, it is unlikely that you will be given too much. There are no known side effects of having too much of Remsima.

If you forget or miss your Remsima infusion If you forget or miss an appointment to receive Remsima, make another appointment as soon as possible.

If you have any further questions on the use of this medicine, ask your doctor.

4. Possible side effects Like all medicines, this medicine can cause side effects, although not everybody gets them. Most side effects are mild to moderate. However some patients may experience serious side effects and may require treatment. Side effects may also occur after your treatment with Remsima has stopped.

Tell your doctor straight away if you notice any of the following:

• Signs of an allergic reaction such as swelling of your face, lips, mouth or throat which may cause difficulty in swallowing or breathing, skin rash, hives, swelling of the hands, feet or ankles. Some of these reactions may be serious or life -threatening. An allergic reaction could happen within 2 hours of your injection or later. More signs of allergic side effects that may happen up to 12 days after your injection include pain in the muscles, fever, joint or jaw pain, sore throat or headache .
• Signs of a heart problem such as chest discomfort or pain, arm pain, stomach pain, shortness of breath, anxiety, lightheadedness, dizziness, fainting, sweating, nausea (feeling sick) , vomiting, fluttering or pounding in your chest, a fast or a slow heartbeat, and swelling of your feet.
• Signs of infection (including TB) such as fever, feeling tired, cough which may be persistent , shortness of breath, flu -like symptoms, weight loss, night sweats, diarrhoea, wounds, collection of pus in the gut or around the anus (abscess), dental problems or burning sensation when urinating .
• Possible signs of cancer including but not limited to swelling of lymph nodes, weight loss, fever, unusual skin nodules, changes in moles or skin colouring, or unusual vaginal bleeding.
• Signs of a lung problem such as coughing, breathing difficulties or tightness in the chest .
• Signs of a nervous system problem (including eye problems) such as signs of a stroke (sudden numbness or weakness of your face, arm or leg, especially on one side of your body; sudden confusion, trouble speaking or understanding; trouble seeing in one or both eyes, trouble walking, dizziness, loss of balance or coordinati on or a severe headache), fits, tingling /numbness in any part of your body, or weakness in arms or legs, changes in eyesight such as double vision or other eye problems .
• Signs of a liver problem (including hepatitis B infection when you have had hepatitis B in the past) such as yellowing of the skin or eyes, dark -brown coloured urine , pain or swelling in the upper right side of the stomach area, joint pain, skin rashes, or fever .
• Signs of an immune system disorder called lupus such as joint pain or a rash on cheeks or arms that is sensitive to the sun (lupus) or cough, shortness of breath, fever or skin rash (sarcoidosis).
• Signs of low blood count s such as persistent fever, bleeding or bruising more easily , small red or purple spots caused by bleeding under the skin, or looking pale.
• Signs of serious skin problems such as reddish -target -like spots or circular patches often with central blisters on the trunk, large areas of peeling and shedding (exfoliating) skin, ulcers of mouth, throat, nose, genitals and eyes or small pus -filled bumps that can spread over the body .

These skin reactions can be accompanied by fever.

Tell your doctor straight away if you notice any of the above.

The following side effects h ave been observed with Remsima:

Very common : may affect more than 1 in 10 people

• Stomach pain, feeling sick
• Viral infections such as herpes or flu
• Upper respiratory infections such as sinusitis
• Headache
• Side effect due to an infusion
• Pain.

Common : may affect up to 1 in 10 people

• Changes in how your liver works, increase in liver enzymes (shown in blood tests)
• Lung or chest infections such as bronchitis or pneumonia
• Difficult or painful breathing, chest pain
• Bleeding in the stomach or intestines, diarrhoea, indigestion, heartburn, constipation
• Nettle -type rash (hives), itchy rash or dry skin
• Balance problems or feeling dizzy
• Fever, increased sweating
• Circulation problems such as low or high blood pressure
• Bruising, hot flush or nosebleed, warm, red skin (flushing)
• Feeling tired or weak
• Bacterial infections such as blood poisoning, abscess or infection of the skin (cellulitis)
• Infection of the skin due to a fungus
• Blood problems such as anaemia or low white blood cell count
• Swollen lymph nodes
• Depression, problems sleeping
• Eye problems, including red eyes and infections
• Fast heart beat (tachycardia) or palpitations
• Pain in the joints, muscles or back
• Urinary tract infection
• Psoriasis, skin problems such as eczema and hair loss
• Reactions at the injection site such as pain, swelling, redness or itching
• Chills, a build -up of fluid under the skin causing swelling
• Feeling numb or having a tingling feeling.

Uncommon : may affect up to 1 in 100 people

• Shortage of blood supply, swelling of a vein
• Collection of blood outside the blood vessels (haematoma) or bruising
• Skin problems such as blistering, warts, abnormal skin colouration or pigmentation, or swollen lips, or thickening of the skin, or red, scaly, and flaky skin
• Severe allergic reactions (e.g. anaphylaxis), an immune system disorder called lupus, allergic reactions to foreign proteins
• Wounds taking longer to heal
• Swelling of the liver (hepatitis) or gall bladder, liver damage
• Feeling forgetful, irritable, confused, nervous
• Eye problems including blurred or reduced vision, puffy eyes or sties
• New or worsening heart failure, slow heart rate
• Fainting
• Convulsions, nerve problems
• A hole in the bowel or blockage of the intestine, stomach pain or cramps
• Swelling of your pancreas (pancreatitis)
• Fungal infections such as yeast infection , or fungal infection of the nails
• Lung problems (such as oedema)
• Fluid around the lungs (pleural effusion)
• Narrowed airway in the lungs, causing difficulty breathing
• Inflamed lining of the lung, causing sharp chest pains that feel worse with breathing (pleurisy)
• Tuberculosis
• Kidney infections
• Low platelet count, too many white blood cells
• Infections of the vagina
• Blood test result showing ‘antibodies’ against your own body.
• Changes in cholesterol and fat levels in the blood.
• Weight gain (for most patients, the weight gain was small) .

Rare : may affect up to 1 in 1,000 people

• A type of blood cancer (lymphoma)
• Your blood not supplying enough oxygen to your body, circulation problems such as narrowing of a blood vessel
• Inflammation of the lining of the brain (meningitis)
• Infections due to a weakened immune system
• Hepatitis B infection when you have had hepatitis B in the past
• Inflamed liver caused by a problem with the immune system (autoimmune hepatitis)
• Liver problem that causes yellowing of the skin or eyes (jaundice)
• Abnormal tissue swelling or growth
• Severe allergic reaction that may cause loss of consciousness and could be life -threatening (anaphylactic shock)
• Swelling of small blood vessels (vasculitis)
• Immune disorders that could affect the lungs, skin and lymph nodes (such as sarcoidosis)
• Collections of immune cells resulting from an inflammatory response (granulomatous lesions)
• Lack of interest or emotion
• Serious skin problems such as toxic epidermal necrolysis, Stevens -Johnson syndrome and acute generalised exanthematous pustulosis
• Other skin problems such as erythema multiforme, blisters and peeling skin, or boils (furunculosis)
• Serious nervous system disorders such as transverse myelitis, multiple sclerosis -like disease, optic neuritis and Guillain -Barré syndrome
• Inflammation in the eye that may cause changes in the vision, including blindness
• Fluid in the lining of the heart (pericardial effusion)
• Serious lung problems (such as interstitial lung disease)
• Melanoma (a type of skin cancer )
• Cervical cancer
• Low blood counts, including a severely decreased number of white blood cells
• Small red or purple spots caused by bleeding under the skin
• Abnormal values of a blood protein called ‘complement factor’ which is part of the immune system
• Lichenoid reactions (itchy reddish -purple skin rash and/or threadlike white -grey lines on mucous membranes).

Not known : frequency cannot be estimated from the available data

• Cancer in children and adults
• A rare blood cancer affecting mostly teenage boys or young men (hepatosplenic T -cell lymphoma)
• Liver failure
• Merkel cell carcinoma (a type of skin cancer )
• Kaposi’s sarcoma, a rare cancer related to infection with human herpes virus 8. Kaposi’s sarcoma most commonly appears as purple lesions on the skin.
• Worsening of a condition called dermatomyositis (seen as a skin rash accompanying muscle weakness)
• Heart attack
• Stroke
• Temporary loss of sight during or within 2 hours of infusion
• Infection due to a live vaccine because of a weakened immune system .

Additional side effects in children and adolescents

Children who took infliximab for Crohn’s disease showed some differences in side effects compared with adults who took infliximab for Crohn’s disease. The side effects that happened more in children were: low red blood cells (anaemia), blood in stool, low overall levels of white blood cells (leukopenia), redness or blushing (flushing), viral infections, low levels of white blood cells that fight infection (neutropenia), bone fracture, bacterial infection and allergic reactions of the breathing tract.

Reporting of side effects

If you get any side effects, talk to your doctor , pharmacist or nurse . This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V . By reporting side effects you can help provide more information on the safety of this medicine.

5. How to store Remsima Remsima will generally be stored by the health professionals. The storage details should you need them are as follows:

• Keep this medicine out of the sight and reach of children.
• Do not use this medicine after the expiry date which is stated on the label and the carton after “EXP”. The expiry date refers to the last day of that month.
• Store in a refrigerator (2 °C – 8°C).
• This medicine can also be stored in the original carton outside of refrigerated storage up to a maximum of 30°C for a single period of up to 15 days , but not beyond the original expiry date .

In this situation, do not return to refrigerated storage again. Write the new expiry date on the carton including day/month/year. Discard this medicine if not used by the new expiry date or the expiry date printed on the carton, whichever is earlier.

• It is recommended that when Remsima is prepared for infusion, it is used as soon as possible (within 3 hours). However, if the solution is prepared in germ -free conditions, it can be stored in a refrigerator at 2 °C – 8°C up to 60 days and for an additional 24 hours at 30 °C after removal from the refrigerator .
• Do not use this medicine if it is discoloured or if there are particles present.

6. Contents of the pack and other information

What Remsima contains

• The active substance is infliximab. Each vial contains 100 mg or 350 mg of infliximab , and each mL contains 40 mg of infliximab.
• The other ingredients are acetic acid, sodium acetate trihydrate, sorbitol (E420), polysorbate 80 (E433) , water for injections .

What Remsima looks like and contents of the pack

Remsima is supplied as a glass vial containing concentrate for solution for infusion. Remsima is a clear to opalescent solution , colourless to pale brown liquid .

Remsima is produced in packs of 1, 2, 3, 4 or 5 vials. Not all pack sizes may be marketed.

Marketing Authorisation Holder

Celltrion Healthcare Hungary Kft.

1062 Budapest Váci út 1 -3. WestEnd Office Building B torony Hungary

Manufacturer

Nuvisan France SARL 2400, Route des Colles, 06410, Biot, France Kymos, SL Ronda De Can Fatjó 7B, Parc Tecnològic del Vallès , Cerdanyola del Vallès, Barcelona, 08290, Spain Midas Pharma GmbH Rheinstraße 49 55218 Ingelheim am Rhein Germany For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder:

België/Belgique/Belgien Celltrion Healthcare Belgium BVBA Tél/Tel: + 32 1528 7418 [email protected] Lietuva Celltrion Healthcare Hungary Kft.

Tel: + 36 1 231 0493 България Celltrion Healthcare Hungary Kft.

Teл.: + 36 1 231 0493 Luxembourg/Luxemburg Celltrion Healthcare Belgium BVBA Tél/Tel: + 32 1528 7418 [email protected] Česká republika Celltrion Healthcare Hungary Kft.

Tel: + 36 1 231 0493 Magyarország Celltrion Healthcare Hungary Kft.

Tel: +36 1 231 0493 Danmark Celltrion Healthcare Denmark ApS [email protected] Tlf: +45 3535 2989 Malta Mint Health Ltd .

Tel: + 356 2093 9800 Deutschland Celltrion Healthcare Deutschland GmbH Tel: + 49 30346494150 [email protected] Nederland Celltrion Healthcare Ne therlands B.V.

Tel: +31 20 888 7300 [email protected] Eesti Celltrion Healthcare Hungary Kft.

Tel: +36 1 231 0493 [email protected] Norge Celltrion Healthcare Norway AS [email protected] Ελλάδα ΒΙΑΝΕΞ Α.Ε.

Τηλ: +30 210 8009111 Ö sterreich Astro -Pharma GmbH Tel.: +43 1 97 99 860 España Kern Pharma, S.L.

Tel: + 34 93 700 25 25 Polska CELLTRION Healthcare Hungary Kft.

Tel.: + 36 1 231 0493 France Celltrion Healthcare France SAS Portugal CELLTRION PORTUGAL, UNIPESSOAL LDA Tel: +33 (0)1 71 25 27 00 Tel: +351 21 936 8542 [email protected] Hrvatska OKTAL PHARMA d.o.o.

Tel: + 385 1 6595 777 Ireland Celltrion Healthcare Ireland Limited Tel: +353 1 223 4026 [email protected] România Celltrion Healthcare Hungary Kft.

Tel: + 36 1 231 0493 Slovenija OPH Oktal Pharma d.o.o.

Tel: + 386 1 519 29 22 Ísland Celltrion Healthcare Hungary Kft.

Sí mi: +36 1 231 0493 [email protected] Slovenská republika Celltrion Healthcare Hungary Kft.

Tel: + 36 1 231 0493 Italia Celltrion Healthcare Italy S.R.L.

Tel: +39 0247927040 [email protected] Suomi/Finland Celltrion Healthcare Finland Oy.

Puh/Tel: +358 29 170 7755 [email protected] Κύπρος C.A. Papaellinas Ltd Τηλ: + 3 57 22741741 Sverige Celltrion Sweden AB [email protected] Latvija Celltrion Healthcare Hungary Kft.

Tel: + 36 1 231 0493 United Kingdom (Northern Ireland) Celltrion Healthcare Ireland Limited Tel: + 353 1 223 4026 This leaflet was last revised in {MM/YYYY}.

Other sources of information Detailed information on this medicine is available on the European Medicines Agency web site: https://www.ema.europa.eu . —————————————————————————————————————————

🩺 Information intended for healthcare professionals only

Patients treated with Remsima should be given the patient reminder card.

Instructions for use and handling – storage conditions Store at 2°C – 8°C.

Remsima may be stored at temperatures up to a maximum of 30°C for a single period of up to 15 days , but not exceeding the original expiry date. The new expiry date must be written on the carton. Upon removal from refrigerated storage, Remsima must not be returned to refrigerated storage.

Instructions for use and handling –dilution and administration In order to improve the traceability of biological medicinal products, the name and batch number of the administered medicinal product should be clearly recorded.

1. The dose and the number of Remsima vials have to be calculated. Each Remsima vial contains either 100 mg or 350 mg infliximab. The required total volume of Remsima concentrate has to be calculated.

2. The required volume of the Remsima concentrate should be withdrawn aseptically and diluted to 250 mL with sodium chloride 9 mg/mL (0.9%) solution for infusion. Do not dilute the Remsima concentrate with any other diluent. The dilution can be accomplished by withdrawing a volume of the sodium chloride 9 mg/mL (0.9%) solution for infusion from the 250 mL glass bottle or infusion bag equal to the required volume of Remsima concentrate. The required volume of Remsima concentrate should slowly be added to the 250-mL infusion bottle or bag and gently be mixed. For volumes greater than 250 mL, either use a larger inf usion bag (e.g. 500 mL , 1000 mL ) or use multiple 250 mL infusion bags to ensure that the concentration of the infusion solution does not exceed 4 mg/ mL. If stored refrigerated after dilution, the infusion solution must be allowed to equilibrate at room temperature (up to 30°C) for 3 hours prior to Step 3 (infusion).

3. The infusion solution has to be administered over a period of not less than the infusion time recommended (see section 3). Only an infusion set with an in -line, sterile, non -pyrogenic, low protein -binding filter (pore size 1.2 micrometr e or less) should be used. Since no preservative is present, it is recommended that the administration of the solution for infusion is to be started as soon as possible and within 3 hours of dilution. If not used immediately, in use storage times and conditions prior to use a re the responsibility of the user and would normally not be longer than 24 hours at 2°C to 8 °C, unless dilution has been taken place in controlled and validated aseptic conditions. Any unused portion of the infusion solution should not be stored for reuse.

4. Remsima should be visually inspected for particulate matter or discolouration prior to administration. If visibly opaque particles, discolouration or foreign particles are observed it should not be used.

5. Any unused medicinal product or waste material should be disposed of in accordance with local requirements.

📄 Package Leaflet – official source

This article reproduces the information in the official package leaflet, as authorised in the European Union. You can consult the original document here: Product information Remsima (PDF, ec.europa.eu).

You can check this medicine at any time in the Union Register of medicinal products (EU number EU/1/13/853).

⚠️ Important: This article is for information purposes only and does not replace medical advice or the package leaflet inside the medicine box. Read the leaflet carefully before use. For any questions about your treatment, talk to your doctor or pharmacist. If you experience side effects, tell your doctor or pharmacist and report them through your national reporting system.